60 Degrees Pharmaceuticals, Inc.
SXTP
$2.85
-$0.06-2.06%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 115.43% | 164.39% | 123.55% | 9.35% | -0.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 115.43% | 164.39% | 123.55% | 9.35% | -0.30% |
| Cost of Revenue | 323.02% | 441.63% | 241.06% | 242.59% | -12.92% |
| Gross Profit | -474.02% | -611.54% | -262.93% | -378.08% | 20.27% |
| SG&A Expenses | 24.09% | 18.46% | 78.62% | 165.61% | 138.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 87.46% | 92.24% | 141.04% | 209.27% | 103.50% |
| Operating Income | -85.60% | -88.68% | -141.92% | -239.10% | -118.59% |
| Income Before Tax | -1,201.94% | -108.61% | -131.35% | 82.14% | 89.98% |
| Income Tax Expenses | -25.00% | -25.00% | -- | 250.00% | 0.00% |
| Earnings from Continuing Operations | -1,201.65% | -108.60% | -131.37% | 82.13% | 89.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -87.01% | -82.12% | 338.64% | 1,969.57% | 3,418.75% |
| Net Income | -1,294.74% | -111.03% | -130.84% | 82.65% | 90.66% |
| EBIT | -85.60% | -88.68% | -141.92% | -239.10% | -118.59% |
| EBITDA | -86.05% | -89.55% | -143.81% | -243.18% | -120.18% |
| EPS Basic | 49.58% | 79.56% | 69.07% | 101.86% | 70.77% |
| Normalized Basic EPS | 68.84% | 83.52% | 75.63% | 71.56% | 52.01% |
| EPS Diluted | 49.58% | 79.56% | 69.07% | 101.86% | 70.77% |
| Normalized Diluted EPS | 68.84% | 83.52% | 75.63% | 71.56% | 52.01% |
| Average Basic Shares Outstanding | 642.00% | 586.39% | 361.62% | 254.31% | 151.27% |
| Average Diluted Shares Outstanding | 642.00% | 586.39% | 361.62% | 254.31% | 151.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |